Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |------------------------------|-----------------------------|----------------------|-------------------------------| | | | | | | FOR THE TRANSITION | PERIOD | FRO ...

If you are looking for a profitable portfolio of stocks offering the best of value and growth investing, try the growth at a reasonable price or GARP strategy.The strategy helps investors gain exposure to undervalued stocks with impressive prospects. Unlike a blend strategy, a portfolio that uses GARP investing is expected to include stocks that offer the best value and growth investing. Cencora, Inc. (COR) , Raymond James Financial (RJF) and Cintas Corporation (CTAS) are some GARP stocks that hold promise. ...

Cencora, Inc. (COR) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 19.7% against 8.9% decline of the industry. The S&P 500 composite has risen 24.5% during the same time frame.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Chesterbrook, PA-based Cencora is one of the world’s largest pharmaceutical service companies. It focuses on providing drug distribut ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Cencora (COR) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Cencora is a member of our Medical group, which includes 1023 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individua ...

Cencora, Inc. (COR) reported fourth-quarter fiscal 2024 adjusted earnings per share (EPS) of $3.34, which beat the Zacks Consensus Estimate of $3.21 by 4%. The bottom line also improved 16.8% year over year.GAAP EPS was 2 cents, down 98.8% from the year-ago period.The significant decline in the fiscal fourth-quarter GAAP EPS has likely resulted from increased operating expenses. This was led by $418 million of goodwill impairment charges related to PharmaLex, along with increased litigation and opioid-relat ...

On Wednesday, Cencora, Inc.’s COR fourth-quarter 2024 sales increased 14.7% to $79.1 billion, beating the consensus of $77.65 billion.  The sales jump reflects a 15.7% increase in revenue within U.S. Healthcare Solutions and a 5.5% increase in revenue within International Healthcare Solutions.The company reported adjusted EPS of $3.34, up 16.8% year over year, beating the consensus of $3.22.Also Read: Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health InsurersConc ...

Cencora, Inc. (NYSE:COR) Q4 2024 Earnings Call Transcript November 6, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR Bob Mauch - President and CEO Laz Krikorian - SVP and CAO Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI George Hill - Deutsche Bank Eric Percher - Nephron Research Stephanie Davis - Barclays Kevin Caliendo - UBS Eric Coldwell - Baird Erin Wright - Morgan Stanley Allen Lutz - Bank of America Charles ...

Cencora (COR) reported $79.05 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 14.7%. EPS of $3.34 for the same period compares to $2.86 a year ago.The reported revenue represents a surprise of +1.76% over the Zacks Consensus Estimate of $77.68 billion. With the consensus EPS estimate being $3.21, the EPS surprise was +4.05%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.21 per share. This compares to earnings of $2.86 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.05%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $3.18 per share when it actually produced earnings of $3.34, delivering a surprise of 5.03%.Over the last four quarters, t ...

cencora Cencora, Inc. Fourth Quarter Fiscal 2024 Earnings Call November 6, 2024 Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," ...